Eastbourne Capital Management News
Most Popular Eastbourne Capital Management Story
Is Amylin caving to proxy pressure?
Is Amylin Pharmaceuticals acting like a kid who won't behave unless his parents threaten punishment? That's what activist shareholders Eastbourne Capital are saying. Sure, Amylin is taking steps to... Read more...
Latest Headlines
- May 28, 2009
- May 27, 2009
- May 22, 2009
- May 18, 2009
- May 6, 2009
- April 23, 2009
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
